Home > Journals > Giornale Italiano di Dermatologia e Venereologia > Past Issues > Giornale Italiano di Dermatologia e Venereologia 2018 April;153(2) > Giornale Italiano di Dermatologia e Venereologia 2018 April;153(2):146-54

CURRENT ISSUE
 

ARTICLE TOOLS

Publication history
Reprints
Cite this article as

GIORNALE ITALIANO DI DERMATOLOGIA E VENEREOLOGIA

A Journal on Dermatology and Sexually Transmitted Diseases


Official Journal of the Italian Society of Dermatology and Sexually Transmitted Diseases
Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,311


eTOC

 

ORIGINAL ARTICLE  


Giornale Italiano di Dermatologia e Venereologia 2018 April;153(2):146-54

DOI: 10.23736/S0392-0488.17.05813-8

Copyright © 2017 EDIZIONI MINERVA MEDICA

language: English

Long-term treatment of psoriatic patients with adalimumab reduces disease severity and maintains a favorable lipid pattern and a low Atherogenic Index

Arianna ZANGRILLI , Mauro BAVETTA, Martina SCARAMELLA, Luca BIANCHI

Department of Dermatology, University Hospital of Tor Vergata, Rome, Italy


PDF  


BACKGROUND: This retrospective study aimed to evaluate the long-term efficacy and effects on lipid profile and Atherogenic Index of antitumor necrosis factor (TNF)α therapy with adalimumab in patients with moderate-to-severe psoriasis or psoriatic arthritis.
METHODS: Sixty-nine psoriatic patients treated with adalimumab 40 mg every other week were included. Patients were treated continuously for four years; study visits took place every 24 weeks. Disease severity (Psoriasis Area Severity Index [PASI], Nail Psoriasis Severity Index [NAPSI], articular pain intensity), disease burden (PSOdisk), serum lipid concentrations, Atherogenic Index, and inflammatory markers were assessed at each visit.
RESULTS: Disease severity improved significantly during treatment. After 24 weeks, 89.9% of patients achieved a PAS I75 response; 79.7% and 46.4% had PASI 90 and PASI 100 responses, respectively. Response was sustained over four years. NAPSI Score, articular pain and disease burden improved significantly. Lipid serum concentrations and inflammatory markers were overall stable and within the range of normality. High-density lipoprotein cholesterol concentrations increased significantly and Atherogenic Index improved. The four years of uninterrupted treatment with adalimumab was well tolerated.
CONCLUSIONS: Long-term treatment of moderate-to-severe psoriatic disease with adalimumab is effective, well tolerated, and potentially beneficial also in terms of lipid pattern and atherogenic risk.


KEY WORDS: Adalimumab - Cardiovascular diseases - Psoriasis - Arthritis, psoriatic

top of page

Publication History

Issue published online: March 20, 2018
Manuscript accepted: November 14, 2017
Manuscript received: October 12, 2017

Cite this article as

Zangrilli A, Bavetta M, Scaramella M, Bianchi L. Long-term treatment of psoriatic patients with adalimumab reduces disease severity and maintains a favorable lipid pattern and a low Atherogenic Index. G Ital Dermatol Venereol 2018;153:146-54. DOI: 10.23736/S0392-0488.17.05813-8

Corresponding author e-mail

arianna.zangrilli@libero.it